康宁杰瑞制药-B（09966）于2026年11月3日在香港联交所场内回购普通股160,000股，占回购前公司已发行股份（不含库藏股）约0.0166%。每股回购价格介乎6.055港元至6.18港元不等，合计支付约97.75万港元。
回购完成后，公司不含库藏股的已发行股份总数降至965,761,697股，库藏股数量增至8,620,000股，合并计算公司已发行股份总数仍为974,381,697股。根据2026年6月12日通过的回购授权，公司可回购股份总数为96,850,669股，目前公司已合计回购2,745,000股，占授权通过当日公司已发行股份（不含库藏股）总数的0.2834%。
公司确认本次回购已符合香港联交所《主板上市规则》等相关规定。公告由执行董事徐霆签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.